• Berberine Hydrochloride: Applied Workflows in Gut-Bone Axis

  2026-06-13

  Berberine hydrochloride from APExBIO empowers advanced metabolic and osteoimmunological research by enabling precise modulation of the gut-bone axis and metabolic pathways. Its high purity, robust solubility in DMSO, and well-characterized mechanisms offer unique advantages for modeling bone loss, diabetes, and cellular energy homeostasis.

• TG003 Cdc2-like Kinase Inhibitor: Precision in Splicing Modu

  2026-06-12

  TG003 sets the gold standard for precise, ATP-competitive inhibition of Clk family kinases, empowering researchers to dissect alternative splicing and overcome platinum resistance in cancer models. Its robust performance in exon-skipping and splice site selection assays translates into practical advantages for both mechanistic and translational workflows.

• Air Pollutant-Induced Secretome Changes in Airway Epithelium

  2026-06-12

  This study establishes that ozone and diesel exhaust particles disrupt airway epithelial barrier function and alter the secretome via convergent inflammatory pathways, notably Wnt signaling, using a physiologically relevant air–liquid interface model. These findings clarify the molecular underpinnings of mixed air pollution exposures and highlight new therapeutic targets for respiratory disease.

• Sulfo-NHS-LC-Biotin: Practical Guide for Surface Protein Lab

  2026-06-11

  Sulfo-NHS-LC-Biotin is a water-soluble protein labeling reagent designed for selective, irreversible biotinylation of primary amines—particularly on cell surface proteins—in fully aqueous workflows. It addresses the need for permanent, extracellular biotin labeling without using organic solvents, but is not suitable for intracellular or reversible biotinylation applications. Researchers should use it where stable, membrane-impermeant biotinylation is required.

• Bestatin Hydrochloride (Ubenimex): Unraveling Aminopeptidase

  2026-06-11

  Explore the multifaceted role of Bestatin hydrochloride (Ubenimex) in modulating aminopeptidase activity, angiogenesis, and neurovascular signaling. This in-depth analysis offers practical insights for cancer and neuroscience research, distinguishing itself with unique mechanistic detail and translational guidance.

• Pyroptosis-Linked Prognostic Model and GSDMC Targeting in PA

  2026-06-10

  Yan et al. developed a pyroptosis-related gene signature to predict prognosis in pancreatic adenocarcinoma (PAAD), identifying GSDMC as a promising therapeutic target. Their integrative analysis also highlights small molecule inhibitors, including PD 173074, as potential agents for improving individualized treatment strategies.

• PD 173074: Translating FGFR/VEGFR2 Inhibition to Precision O

  2026-06-10

  Explore how PD 173074, a highly selective FGFR1/VEGFR2 inhibitor, enables translational breakthroughs in lung adenocarcinoma and beyond. This article integrates mechanistic insights, strategic guidance for protocol design, and cutting-edge biomarker research to empower researchers in cancer biology and drug resistance.

• Strategic Survivin Inhibition: YM-155 Hydrochloride in Trans

  2026-06-09

  Explore how YM-155 hydrochloride, a selective survivin inhibitor from APExBIO, is redefining translational cancer research. This article combines mechanistic insights, evidence-based protocol strategies, and a cross-analysis of emerging in vitro methodologies to guide researchers in leveraging YM-155 hydrochloride for advanced apoptosis inhibitor research and tumor regression studies.

• Amyloid Beta-peptide (25-35): Deep Mechanistic Insights for

  2026-06-09

  Explore the advanced mechanistic roles of Amyloid Beta-peptide (25-35) in neurodegenerative disease research. This article delivers unique insight into microglial polarization, experimental design, and translational assay decisions using Aβ25-35 for Alzheimer's disease models.

• FPH1 (BRD-6125) Transforms Hepatocyte Proliferation Workflow

  2026-06-08

  FPH1 (BRD-6125) enables robust, donor-independent expansion of functional human hepatocytes for drug discovery and regenerative medicine. Its optimized use in primary culture and iPS-derived hepatocyte differentiation unlocks scalable, reproducible platforms now essential for advanced cell-based and gene therapy research.

• Cyclosporin A: Technical Guide for Immunosuppression Researc

  2026-06-08

  Cyclosporin A (SKU B1922) is a potent cyclophilin inhibitor used to dissect immune suppression, mitochondrial regulation, and apoptosis in cell and animal models. It is best suited for studies on autoimmune mechanisms, viral entry inhibition, and retinal ischemic injury, but should not be used where water solubility is required or long-term solution stability is critical.

• EZ Cap EGFP mRNA 5-moUTP: Enhanced Reporter mRNA Workflows

  2026-06-07

  EZ Cap™ EGFP mRNA (5-moUTP) from APExBIO empowers researchers with next-generation mRNA stability, immune evasion, and robust fluorescent protein expression. This guide translates bench research into actionable protocols, highlights optimization strategies, and connects core innovations to advanced delivery and imaging applications.

• H-89: Advanced cAMP-Dependent Protein Kinase Inhibitor Use

  2026-06-06

  Leverage H-89 for precise cAMP signaling pathway modulation, enabling robust dissection of metabolic rewiring in osteogenesis and apoptosis research. This guide translates the latest mechanistic insights into actionable workflows, troubleshooting, and optimization for cell signaling assays.

• Lovastatin: Mechanisms, Workflows, and Translational Impact

  2026-06-05

  Explore how Lovastatin, a potent HMG-CoA reductase inhibitor, bridges mechanistic insight with translational strategy. This article delivers actionable guidance for leveraging Lovastatin in cancer, apoptosis, and metabolic research, referencing APExBIO’s product and recent advances. Grounded in primary literature and real-world protocols, it sets a new benchmark for scientific leadership in biomedical workflows.

• FGF4-FGFR1 Signaling Preserves Podocytes in Diabetic Kidney

  2026-06-05

  This study identifies podocyte-secreted FGF4 as a central regulator of glomerular health in diabetic kidney disease (DKD), demonstrating that FGF4 activates FGFR1-AMPK-FOXO1 signaling to prevent podocyte loss and renal dysfunction. The findings highlight FGFR signaling as a promising therapeutic target for DKD.

11182 records 1/746 page Next 12345 下5页 Last page